Armeen Mahvash, MD

Armeen Mahvash, MD is a Professor in the Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.

Articles by Armeen Mahvash, MD

Armeen Mahvash, MD, professor, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center; assistant professor, Department of Diagnostic and Interventional Imaging, The University of Texas Medical School at Houston

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

ByArmeen Mahvash, MD

October 27th 2025

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Professor, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Dr Mahvash on the Clinical Impact of the FDA Approval of SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC

ByArmeen Mahvash, MD

October 16th 2025

Armeen Mahvash, MD, discusses the clinical impact of the FDA approval of SIR-Spheres Y-90 resin microspheres for unresectable hepatocellular carcinoma.

Armeen Mahvash, MD

Articles by Armeen Mahvash, MD

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

Dr Mahvash on the Clinical Impact of the FDA Approval of SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma